Skip to main content
SpringerLink
Log in

Chronic Myeloid Leukemia, BCR-ABL1 Positive

  • Living reference work entry
  • First Online:
Encyclopedia of Pathology

Part of the book series: Encyclopedia of Pathology ((EP))

  • 64 Accesses

Synonyms

Chronic myelogenous leukemia

Definition

Chronic myeloid leukemia (CML) represents the clonal and neoplastic proliferation of a hematopoietic stem cell with a chromosomal translocation t(9;22) and junction of the BCR-gene and ABL-gene resulting in a BCR-ABL fusion protein of 210 kD or 190 kD, and leading to growth factor independent proliferation and leucocytosis. Non-neoplastic stem cells are vergrown but differentiation and maturation are retained by neoplastic cells with sufficient production of blood cells. In untreated patients, the steady state phase (chronic phase) with sufficient production of mature blood cells usually progresses to an accelerated phase with deterioration of hematologic blood parameters and/or organomegaly. Differentiation of the transformed hemaopoietic stem cells gets lost after a period of about 3 years (median) resulting in the blast phase. Transition from chronic to accelerated and blast phase, respectively, is defined by a number of parameters,...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References and Further Reading

  • Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R. T., Goldman, J., Hehlmann, R., & European LeukemiaNet. (2009). Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041–6051.

    Article  CAS  Google Scholar 

  • Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F., & Rosti, G. (2014). Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Expert Review of Hematology, 7, 397–406.

    Article  CAS  Google Scholar 

  • Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., Reilly, J. T., Vannucchi, A. M., Hanson, C. A., Solberg, L. A., Orazi, A., Tefferi, A., & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2008). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437–438.

    Article  CAS  Google Scholar 

  • Bartels, S., Lehmann, U., Büsche, G., Schlue, J., Mozer, M., Stadler, J., Triviai, I., Alchalby, H., Kröger, N., & Kreipe, H. (2015). SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia, 29, 253–255.

    Article  CAS  Google Scholar 

  • Bartels, S., Faisal, M., Büsche, G., Schlue, J., Kreipe, H., & Lehmann, U. (2018). Fibrotic progression in polycythemia vera is associated with early concomitant driver-mutations besides JAK2. Leukemia, 32, 556–558.

    Article  CAS  Google Scholar 

  • Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H., Sultan, C., & Cox, C. (1994). The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British co-operative leukaemia group. British Journal of Haematology, 87, 746–754.

    Article  CAS  Google Scholar 

  • Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D. W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., Garcia-Gutierrez, V., Reilly, L., Jeynes-Ellis, A., Leip, E., Bardy-Bouxin, N., Hochhaus, A., & Brümmendorf, T. H. (2018). Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. Journal of Clinical Oncology, 36, 231–237. https://doi.org/10.1200/JCO.2017.74.7162.

    Article  CAS  PubMed  Google Scholar 

  • Deininger, M. W. (2015). Diagnosing and managing advanced chronic myeloid leukemia. American Society of Clinical Oncology Educational Book, e381–388.

    Article  Google Scholar 

  • Fialkow, P. J., Martin, P. J., Najfeld, V., Penfold, G. K., Jacobson, R. J., & Hansen, J. A. (1981). Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood, 58, 158–163.

    CAS  PubMed  Google Scholar 

  • Hehlmann, R., Saußele, S., Voskanyan, A., & Silver, R. T. (2016). Management of CML-blast crisis. Best Practice & Research. Clinical Haematology, 29, 295–307.

    Article  Google Scholar 

  • Hijiya, N., Schultz, K. R., Metzler, M., Millot, F., & Suttorp, M. (2016). Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood, 127, 392–399.

    Article  CAS  Google Scholar 

  • Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C. E., Menssen, H. D., Kantarjian, H., O’Brien, S. G., Druker, B. J., & IRIS Investigators. (2017). Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. The New England Journal of Medicine, 376(10), 917–927. https://doi.org/10.1056/NEJMoa1609324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hussein, K., Bock, O., Seegers, A., Flasshove, M., Henneke, F., Buesche, G., & Kreipe, H. H. (2007). Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood, 109(9), 4106–4107.

    Article  CAS  Google Scholar 

  • Kantarjian, H. M., Dixon, D., Keating, M. J., Talpaz, M., Walters, R. S., McCredie, K. B., & Freireich, E. J. (1988). Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer, 61, 1441–1446.

    Article  CAS  Google Scholar 

  • Khalidi, H. S., Brynes, R. K., Medeiros, L. J., Chang, K. L., Slovak, M. L., Snyder, D. S., & Arber, D. A. (1998). The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in “lymphoid” blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Modern Pathology, 11, 1211–1221.

    CAS  PubMed  Google Scholar 

  • Lehmann, U., Bartels, S., Hasemeier, B., Geffers, R., Schlue, J., Büsche, G., Hussein, K., & Kreipe, H. (2013). SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis. Blood, 121, 4011–4012.

    Article  CAS  Google Scholar 

  • Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R., & Skoda, R. C. (2014). Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood, 123, 2220–2228.

    Article  CAS  Google Scholar 

  • Melo, J. V. (1996). The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 88, 2375–2384.

    CAS  PubMed  Google Scholar 

  • Melo, J. V., & Barnes, D. J. (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer, 7, 441–453. https://doi.org/10.1038/nrc2147.

    Article  CAS  PubMed  Google Scholar 

  • Melo, J. V., Myint, H., Galton, D. A., & Goldman, J. M. (1994). P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia. Leukemia, 8, 208–211.

    CAS  PubMed  Google Scholar 

  • Mesa, R. A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J. T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M. C., Wadleigh, M., Campbell, P. J., Silver, R. T., Vannucchi, A. M., Deeg, H. J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L. A., Gotlib, J., Hexner, E., Nimer, S. D., Kantarjian, H., Orazi, A., Vardiman, J. W., Thiele, J., Tefferi, A., & International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2007). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 31, 737–740.

    Article  Google Scholar 

  • Mukherjee, S., & Kalaycio, M. (2016). Accelerated phase CML: Outcomes in newly diagnosed vs. progression from chronic phase. Current Hematologic Malignancy Reports, 11, 86–93. https://doi.org/10.1007/s11899-016-0304-7.

    Article  PubMed  Google Scholar 

  • Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., Godfrey, A. L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Döhner, K., Harrison, C. N., Vassiliou, G. S., Vannucchi, A., Campbell, P. J., & Green, A. R. (2015). Effect of mutation order on myeloproliferative neoplasms. The New England Journal of Medicine, 372, 601–612.

    Article  Google Scholar 

  • Pane, F., Frigeri, F., Sindona, M., Luciano, L., Ferrara, F., Cimino, R., Meloni, G., Saglio, G., Salvatore, F., & Rotoli, B. (1996). Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood, 88, 2410–2414.

    CAS  PubMed  Google Scholar 

  • Reid, A. G., De Melo, V. A., Elderfield, K., Clark, I., Marin, D., Apperley, J., & Naresh, K. N. (2009). Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leukemia Research, 33, 418–425.

    Article  Google Scholar 

  • Silverstein, M. N. (1976). The evolution into and the treatment of late stage polycythemia vera. Seminars in Hematology, 13, 79–84.

    CAS  PubMed  Google Scholar 

  • Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., Porkka, K., Baccarani, M., Cross, N. C., & Martinelli, G. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118, 1208–1215.

    Article  CAS  Google Scholar 

  • Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V., Hochhaus, A., Kim, D. W., Kim, T. D., Khoury, H. J., Le Coutre, P., Mayer, J., Milojkovic, D., Porkka, K., Rea, D., Rosti, G., Saussele, S., Hehlmann, R., & Clark, R. E. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 30, 1648–1671.

    Article  CAS  Google Scholar 

  • van Rhee, F., Hochhaus, A., Lin, F., Melo, J. V., Goldman, J. M., & Cross, N. C. (1996). p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood, 87, 5213–5217.

    PubMed  Google Scholar 

  • Vannucchi, A. M., & Harrison, C. N. (2017). Emerging treatments for classical myeloproliferative neoplasms. Blood, 129, 693–703.

    Article  CAS  Google Scholar 

  • Vardiman, J. W., Melo, J. V., Baccarani, M., Radich, J. P., & Kvasnicka, H. M. (2017). Chronic myelogenous leukemia, BCR-ABL1 positive. In S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, J. Thiele, D. A. Arber, R. P. Hasserjian, L. B. MM, A. Orazi, & R. Siebert (Eds.), WHO classification of haematopoietic and lymphoid tissues (pp. 30–36). Lyon: IARC Press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology Hannover Medical School, Hannover, Germany

    Hans Kreipe

Authors
  1. Hans Kreipe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Kreipe .

Editor information

Editors and Affiliations

  1. NIJMEGEN, The Netherlands

    J.H.J.M. van Krieken

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kreipe, H. (2019). Chronic Myeloid Leukemia, BCR-ABL1 Positive. In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_5013-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28845-1_5013-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28845-1

  • Online ISBN: 978-3-319-28845-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation